Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study

被引：0
|
作者：
Shiori Hishida-Sadaka
Hirotoshi Iihara
Koichi Ohata
Serika Matsuoka
Daichi Watanabe
Takuji Iwashita
Shinya Uemura
Masahito Shimizu
Akio Suzuki
机构：
[1] Gifu University Hospital,Department of Pharmacy
[2] Gifu University Hospital,Patient Safety Division
[3] Gifu Pharmaceutical University,Laboratory of Pharmacy Practice and Social Science
[4] Gifu University Graduate School of Medicine,Department of Gastroenterology
[5] Gifu Pharmaceutical University,Laboratory of Advanced Medical Pharmacy
来源：
Supportive Care in Cancer | 2023年 / 31卷
关键词：
Advanced pancreatic cancer; Antiemetic therapy; Chemotherapy; Chemotherapy-induced nausea and vomiting;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 45 条
  • [1] Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study
    Hishida-Sadaka, Shiori
    Iihara, Hirotoshi
    Ohata, Koichi
    Matsuoka, Serika
    Watanabe, Daichi
    Iwashita, Takuji
    Uemura, Shinya
    Shimizu, Masahito
    Suzuki, Akio
    [J]. SUPPORTIVE CARE IN CANCER, 2023, 31 (12)
  • [2] 5HT3RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer
    Hayashi, Toshinobu
    Shimokawa, Mototsugu
    Matsuo, Koichi
    Nishimura, Junichi
    Iihara, Hirotoshi
    Nakano, Takafumi
    Egawa, Takashi
    [J]. CANCER SCIENCE, 2021, 112 (02) : 744 - 750
  • [3] USE OF THE 5-HT3-RA ANTIEMETICS IN THE PREVENTION AND TREATMENT OF RADIATION INDUCED NAUSEA AND VOMITING
    Knoth, R. L.
    Faria, C.
    Chang, E.
    Broder, M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A408 - A409
  • [4] Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis
    Faria, Claudio
    Li, Xuan
    Nagl, Norman
    McBride, Ali
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2014, 7 (01): : 50 - 58
  • [5] CHARGES ASSOCIATED WITH CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN CANCER PATIENTS INITIATING AND MAINTAINING THERAPY WITH A 5-HT3-RA THROUGHOUT CHEMOTHERAPY CYCLES
    Faria, C.
    Nagl, N.
    Li, X.
    Powers, A.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A133 - A133
  • [6] Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study
    Swu-Jane Lin
    Hind T Hatoum
    Deborah Buchner
    David Cox
    Sanjeev Balu
    [J]. BMC Health Services Research, 12
  • [7] Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study
    Lin, Swu-Jane
    Hatoum, Hind T.
    Buchner, Deborah
    Cox, David
    Balu, Sanjeev
    [J]. BMC HEALTH SERVICES RESEARCH, 2012, 12
  • [8] THE EFFICACY AND SAFETY OF MODIFIED FOLFIRINOX FOR UNRESECTABLE ADVANCED PANCREATIC CANCER IN ELDERLY VERSUS YOUNG PATIENTS: A MULTICENTER RETROSPECTIVE COHORT STUDY
    Tezuka, Ryuichi
    Iwashita, Takuji
    Uemura, Shinya
    Senju, Akihiko
    Yoshida, Kensaku
    Maruta, Akinori
    Iwata, Keisuke
    Shimizu, Masahito
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S603 - S603
  • [9] The efficacy and safety of modified FOLFIRINOX for unresectable advanced pancreatic cancer in elderly versus young patients: A multicenter retrospective cohort study
    Tezuka, Ryuichi
    Iwashita, Takuji
    Uemura, Shinya
    Senju, Akihiko
    Yoshida, Kensaku
    Maruta, Akinori
    Iwata, Keisuke
    Shimizu, Masahito
    [J]. PANCREATOLOGY, 2022, 22 (08) : 1134 - 1140
  • [10] Intergenerational comparison of 5-HT3RA in the prevention of chemotherapy-induced nausea and vomiting in gastric cancer patients receiving cisplatin-based chemotherapy: an observational study using a Japanese administrative claims database
    Yuji Kunitomi
    Masayuki Nakashima
    Tomotsugu Seki
    Kazuki Ide
    Koji Kawakami
    [J]. Supportive Care in Cancer, 2021, 29 : 3951 - 3959
12345